


Title	The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
Author(s)	Murai, Kazuhiro; Hikita, Hayato; Yamada, Ryoko et al.
Citation	Hepatology Research. 2025, 55(9), p. 1228-1238
Version Type	VoR
URL	https://hdl.handle.net/11094/102751
rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Note	

The University of Osaka Institutional Knowledge Archive : OUKA

https://ir.library.osaka-u.ac.jp/

The University of Osaka







ORIGINAL ARTICLE OPEN ACCESS

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs

¹Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan | ²Department of Medical Innovation, The University of Osaka Hospital, Suita, Japan | ³Department of Gastroenterology, Osaka Keisatsu Hospital, Suita, Japan | ⁴Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Japan | ⁵Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, Sakai, Japan | ⁵Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, Sakai, Japan | ⁵Department of Gastroenterology and Hepatology, Japan Community Healthcare Organization Osaka Hospital, Osaka, Japan | ³Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan | ³Department of Gastroenterology and Hepatology, Otemae Hospital, Osaka, Japan | ¹Department of Gastroenterology and Hepatology, Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami, Japan | ¹²Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Suita, Japan | ¹³Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan | ¹⁴Department of Gastroenterology and Hepatology, Itami City Hospital, Itami, Japan | ¹⁵Department of Gastroenterology and Hepatology, Minoh City Hospital, Minoh, Japan | ¹⁶Department of Gastroenterology and Hepatology, Nishinomiya Municipal Central Hospital, Nishinomiya, Japan | ¹⁰Department of Gastroenterology, Nishinomiya Municipal Central Hospital, Nishinomiya, Japan | ¹⁰Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan | ²¹Department of Gastroenterology and Hepatology, Toyonaka Municipal Hospital, Toyonaka, Japan | ²¹Department of Gastroenterology and Hepatology, Koga Community Hospital, Koga, Japan

Correspondence: Tetsuo Takehara (takehara@gh.med.osaka-u.ac.jp)

Received: 6 January 2025 | Revised: 16 May 2025 | Accepted: 2 June 2025

Funding: This study was funded by the Japan Agency for Medical Research and Development (AMED) under grant numbers JP24fk0310512 (H.H., T.Tat. and T.Tak.) and JP25fk0310534 (K.Mu., H.H. and T.K.).

Keywords: CHB | cirrhosis | HBV | HCC | NUC

ABSTRACT

Background and Aim: Nucleos(t)ide analogs (NUCs) are used in the treatment of chronic hepatitis B (CHB). It is still uncertain whether the risk of incident hepatocellular carcinoma (HCC) continues beyond 5 or 10 years after the initiation of NUC treatment. We aimed to elucidate this in CHB patients receiving long-term NUC treatment.

Methods: This was a multicenter, observational study that included patients who began NUC treatment between July 2000 and March 2019; patients were retrospectively enrolled up to March 2019 and followed up until August 2024.

Abbreviations: ALD, alcohol-associated liver disease; BMI, body mass index; CHB, chronic hepatitis B; CI, confidence interval; ETV, entecavir; GDF15, growth differentiation factor 15; HBcrAg, hepatitis B virus core-related antigen; HBe antigen, hepatitis B eantigen; HBs antigen, hepatitis B surface antigen; HBs application associated structures; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HR, hazard ratio; IFN, interferon; LAM, lamivudine; MASLD, metabolic dysfunction-associated steatotic liver disease; NUC, nucleos(t)ide analog; OLF, Osaka Liver Forum; SGLT2, sodium-glucose cotransporter 2; SNP, single-nucleotide polymorphism; SVR, sustained virological response; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2025 The Author(s). Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.

Results: Among 737 CHB patients (156 with cirrhosis) who started NUC treatment, 147 developed HCC during a median follow-up period of 144.2 months. The 5-, 10-, and 15-year cumulative HCC rates were 11.2%, 18.4%, and 23.1%, respectively. Independent risk factors for subsequent HCC occurrence included older age, male sex, cirrhosis, low platelet count, low ALT levels, and high γ -GTP levels at NUC initiation. After 5 years, the risk factors were cirrhosis, high γ -GTP levels, and high AFP levels, whereas after 10 years, they were cirrhosis and diabetes. Landmark analysis revealed that the 5-year cumulative HCC incidence was 8.1% at 5 years and 5.8% at 10 years after NUC initiation. In noncirrhotic patients, cumulative HCC incidence at 5 years was 5.8%, whereas 5-year cumulative incidences starting at 5 and 10 years were 4.1% and 4.8%, respectively, remaining stable over time.

Conclusion: The risk of HCC persists long after NUC initiation. In noncirrhotic patients, the risk remains stable more than 10 years after NUC treatment initiation.

1 | Introduction

Hepatocellular carcinoma (HCC) is currently the third most common cause of cancer-related death globally [1], and chronic hepatitis B virus (HBV) infection is recognized as a significant risk factor. HBV infection poses a significant global public health challenge. Approximately 296 million individuals worldwide are estimated to be hepatitis B surface antigen (HBs antigen)-positive, with 820,000 deaths occurring each year due to HBV-related liver cirrhosis and hepatocellular carcinoma [2].

Currently, the anti-HBV therapies available for clinical use are interferon (IFN) and nucleos(t)ide analogs (NUCs) [3, 4]. Treatment with NUCs lowers serum HBV DNA titers and reduces the risk of HCC [5–8]. Even in patients who achieve viral suppression after several years of NUC therapy, the risk of HCC persists [5, 8]. The proportion of patients with HBV infection as the etiology of HCC has not decreased worldwide [9–11].

Currently, many chronic hepatitis B patients receive long-term NUC treatment. However, it is not clear whether the risk of HCC changes after prolonged treatment with NUCs, that is, treatment lasting for more than 5 or 10 years in chronic hepatitis B (CHB) patients. Evaluating the risk of HCC in patients receiving long-term NUC treatment and the effect of long-term NUC treatment on HCC is important for HCC surveillance in CHB patients receiving NUC treatment. In the present study, we collected data from CHB patients who received initial treatment with NUCs between July 2000 and March 2019 at multiple centers. Here, we identified the risk factors linked to the development of incident HCC in CHB patients receiving long-term NUC treatment and the suppressive effect of prolonged NUC therapy on the occurrence of incident HCC.

2 | Methods

2.1 | Study Design

The present study was a multicenter, observational investigation. Patients who received their first dose of NUCs between July 2000 and March 2019 at The University of Osaka Hospital and 18 affiliated facilities of the Osaka Liver Forum (OLF) (Supporting Information S3: Table S1) were retrospectively included, with follow-up extending until August 2024. Patients with a history of HCC, patients with HBV DNA titers below the level of detection at the start of NUC treatment, patients

receiving concomitant IFN at the start of NUC treatment, and patients with other liver diseases (hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection, autoimmune diseases) or liver transplant were excluded. We assessed the incidence rate of HCC during NUC therapy. Patients who discontinued NUC treatment, who were transferred to another hospital, or who died were censored. Cirrhosis was diagnosed on the basis of liver biopsy, imaging, or portal hypertension, as reported in previous studies [6]. Diabetes mellitus was determined by treatment for diabetes. To examine the incidence of HCC more than 5 or 10 years after NUC treatment initiation, a landmark analysis was conducted using the 5-year or 10-year mark as the starting point.

2.2 | HBV DNA

HBV DNA was measured through the COBAS Amplicor HBV Monitor test (detection range 2.6 to 7.6 log copies/mL), the COBAS TaqMan HBV test v2.0 (detection range 1.8 to 8.8 log copies/mL), or the COBAS 6800/8800 system HBV test (detection range 1.0 to 9.0 log IU/mL), depending on the timing and facility. In accordance with the manufacturer's guidelines and the recommendations of the Japan Society of Hepatology, HBV DNA values were converted from log copies/mL to log IU/mL [12].

2.3 | Statistical Analysis

Statistical analyses were conducted through JMP version 17.1.0 (SAS Institute, Cary, USA) and EZR software [13]. Categorical data were analyzed through the chi-square test. The Mann-Whitney U test was used for continuous or ordinal data. The Kaplan-Meier method was used to estimate the cumulative incidence rates of HCC, and log-rank tests were used to evaluate the differences between cirrhotic and noncirrhotic patients. The Cox proportional hazards model was used to identify the independent factors associated with the occurrence of incident HCC. As factors for the multivariate analysis, we selected significant factors from the univariate analysis, excluding those with 30% or more missing values, unless otherwise specified. The risks are presented as hazard ratios (HRs) along with 95% confidence intervals (CIs). The Schoenfeld residual test was used to verify the proportional hazards model. A p-value < 0.05 was considered significant.

2.4 | Ethics Approval

This study was conducted in accordance with the principles outlined in the Declaration of Helsinki, the Ethical Guidelines for Clinical Studies from the Japanese Ministry of Health, Labour and Welfare, and all relevant laws in Japan. Approval for this study was obtained from the Ethics Review Committee of The University of Osaka Hospital (12,380), and the study protocol was approved by each participating institution. This research was conducted as an observational study without the use of human biological samples. As a result, written informed consent was not necessary from individual patients for the use of their clinical records, in accordance with the ethical guidelines provided by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan. The complete details of this study were made publicly available, and patients were given the option to opt out by accessing the study information on the institutions' websites.

3 | Results

3.1 | Characteristics in the Present Study

A total of 737 patients who began NUC treatment between July 2000 and March 2019 were included in this study. At the time of NUC treatment initiation, 175 patients were treated with lamivudine (LAM), 516 with entecavir (ETV), 23 with tenofovir disoproxil fumarate (TDF), and 23 with tenofovir alafenamide (TAF). The median age of the patients was 53 years, with 59.2% being male. Among them, 45.5% were positive for hepatitis B e antigen (HBe antigen), and 11.3% had diabetes mellitus. Cirrhosis was present in 156 patients (21.2%). The median observation period was 144.2 months. At the initiation of NUC treatment, the group of patients with cirrhosis was older; had higher proportions of males, patients with diabetes mellitus, and LAM administration; had significantly lower platelet counts; had lower ALT, albumin, and PT levels; and had higher γ -GTP, total bilirubin, and AFP levels than did the group of patients without cirrhosis (Table 1). γ -GTP levels did not correlate with body mass index (BMI), whereas diabetes mellitus and alcohol intake were associated with high γ -GTP levels (Supporting Information S2: Figure S1A-C).

3.2 | Cumulative Incidence of HCC After the Initiation of NUC Treatment and Risk Factors for Incident HCC

Among the 737 patients, 147 developed HCC; 63 patients were positive and 81 were negative for HBe antigen, and 81 patients had cirrhosis, whereas 66 did not. The cumulative incidence of HCC after the initiation of NUC was 11.2% at 5 years, 18.4% at 10 years, and 23.1% at 15 years (Figure 1A). The Cox proportional hazards model revealed that older age, male sex, the presence of cirrhosis, a low platelet count, a low ALT level, and a high γ -GTP level at the time of NUC treatment initiation were independent risk factors for incident HCC (Table 2). The HBs

antigen was identified as a risk factor for incident HCC in the univariate analysis; however, it was excluded from the multivariate analysis because 49.0% of the data were missing (Table 2). The type of NUC at the start of NUC treatment was not identified as a risk factor for incident HCC in either the univariate analysis (Table 2) or the multivariate analysis (Supporting Information S3: Table S2). When patients were analyzed separately by HBe antigen status, the Cox proportional hazards model identified older age and cirrhosis as independent risk factors for incident HCC in HBe antigen-positive patients, whereas older age, male sex, low platelet count, and high γ -GTP levels were independent risk factors in HBe antigen-negative patients (Supporting Information S3: Tables S3–S6).

3.3 | Cumulative HCC Incidence Stratified by the Presence or Absence of Cirrhosis and Risk Factors for HCC Development at 5 or 10 Years After NUC Initiation

The cumulative HCC incidence in cirrhotic patients was 7.1% at 1 year, 16.8% at 2 years, 26.0% at 3 years, 30.0% at 4 years, 36.8% at 5 years, 49.5% at 10 years, and 55.5% at 15 years, which was significantly greater than the cumulative HCC incidence in noncirrhotic patients (1.2% at 1 year, 1.9% at 2 years, 2.8% at 3 years, 3.4% at 4 years, 4.1% at 5 years, 9.7% at 10 years, and 14.0% at 15 years) (Figure 1B). When the risk factors for subsequent incident HCC at 5 or 10 years after NUC treatment initiation were examined, a Cox proportional hazards model revealed that older age, the presence of cirrhosis at baseline, high γ -GTP levels at 5 years after NUC treatment, and high AFP levels at 5 years after NUC treatment were independent risk factors for incident HCC after 5 years of NUC treatment and that the presence of cirrhosis and diabetes at baseline were independent risk factors for incident HCC after 10 years of NUC treatment (Tables 3 and 4). Among patients with normal ALT levels at 5 years after NUC treatment, older age, the presence of cirrhosis, and high γ -GTP levels at 5 years after NUC treatment were independent risk factors for incident HCC after 5 years of NUC treatment (Supporting Information S3: Tables S7 and S8).

3.4 | Cumulative Incidence of HCC After 5 or 10 Years of NUC Treatment

To examine the risk of incident HCC more than 5 or 10 years after NUC treatment initiation, we conducted a landmark analysis using the 5-year or 10-year mark as the starting point. After 5 years of NUC treatment, among the 737 patients, 593 patients, including 92 cirrhotic patients, continued NUC treatment without developing HCC (Supporting Information S3: Table S9). After 10 years of NUC treatment, among the 737 patients, 421 patients, including 59 cirrhotic patients, continued NUC treatment without developing HCC (Supporting Information S3: Table S10). Landmark analysis revealed that the 5-year and 10-year cumulative incidence rates of HCC starting 5 years after NUC treatment initiation were 8.1% and 13.4%, respectively

TABLE 1 | Patient characteristics at the start of NUC treatment.

	Total	Noncirrhosis	Cirrhosis	<i>p</i> -value	Missing values
Number of patients	737	581	156		
Age (median, range)	53 (15-82)	51 (15-82)	57 (32-81)	< 0.0001	0
Sex (male, female)	436/301 (59.2%, 40.8%)	332/249 (57.1%, 42.9%)	104/52 (66.7%, 33.3%)	0.0317	0
BMI (kg/m^2) (< 23, 23 \leq)	268/258 (51.0%, 49.0%)	220/197 (52.8%, 47.2%)	48/61 (44.0%, 56.0%)	0.1049	211
Average daily alcohol intake (g) $(< 20, 20 \le)$	251/165 (60.3%, 39.7%)	202/137 (59.6%, 40.4%)	49/28 (63.6%, 36.4%)	0.5120	321
Diabetes mellitus (+, -)	83/654 (11.3%, 88.7%)	51/530 (8.8%, 91.2%)	32/124 (20.5%, 79.5%)	< 0.0001	0
NUC at the start of NUC treatment (LAM, ETV, TDF/TAF)	175/516/46 (23.8%, 70.0%, 6.2%)	126/414/41 (21.7%, 71.3%, 7.0%)	49/102/5 (31.4%, 65.4%, 3.2%)	0.0148	0
HBs antigen (IU/mL) (< 250, 250 ≤)	49/327 (13.0%, 87.0%)	45/265 (14.5%, 85.5%)	4/62 (6.1%, 93.9%)	0.0639	361
HBe antigen (+, -)	324/388 (45.5%, 54.5%)	250/310 (44.6%, 55.4%)	74/78 (48.7%, 51.3%)	0.3749	25
HBV DNA (log IU/mL) (median, range)	6.0 (1.4-8.4)	6.0 (1.4-8.4)	6.2 (1.5-8.3)	0.6483	0
HBcrAg (log U/mL) ($< 3.0, 3.0 \le$)	13/59 (18.1%. 81.9%)	12/49 (19.7%, 80.3%)	1/10 (9.1%, 90.9%)	0.4010	665
Platelet ($\times 10^4/\mu L$) (median, range)	15.7 (2.8-54.0)	16.9 (3.9–54.0)	9.5 (2.8–35.7)	< 0.0001	7
AST (IU/L) (median, range)	57 (15–1533)	54 (15-1533)	60 (25-659)	0.1771	173
ALT (IU/L) (median, range)	70 (7–2986)	76 (8–2986)	60 (7-689)	0.0009	1
γ-GTP (IU/L) (median, range)	47 (9–1001)	43 (9–1001)	60 (12-720)	0.0001	55
Total bilirubin (mg/dL) (median, range)	0.8 (0.3-28.5)	0.8 (0.3-10.1)	1.0 (0.4–28.5)	< 0.0001	8
Albumin (g/dL) (median, range)	4.0 (1.4-5.1)	4.1 (1.4-5.1)	3.6 (1.6-4.7)	< 0.0001	19
PT (%) (median, range)	83 (30–138)	86 (30–138)	69 (40–107)	< 0.0001	132
AFP (ng/mL) (median, range)	6 (1–2370)	5 (1–1509)	14 (1-2370)	< 0.0001	142
Creatinine (mg/dL) (median, range)	0.70 (0.057-8.26)	0.70 (0.09-8.26)	0.72 (0.057-3.10)	0.6872	103
Observation period (months)	144.2 (1.6-292.3)	154.3 (1.6-292.3)	80.4 (3.1-285.7)	< 0.0001	0

(Figure 2A). The 5-year cumulative incidence of HCC starting 10 years after NUC treatment initiation was 5.8% (Figure 2B).


3.5 | The HCC Incidence Rate in Cirrhotic Patients Remains Higher Than That in Noncirrhotic Patients After Long-Term NUC Treatment

When cirrhotic and noncirrhotic patients were analyzed separately, the cumulative incidence of HCC starting 5 or 10 years after NUC treatment initiation was significantly greater in cirrhotic patients than in noncirrhotic patients (Figure 2C, Figure 2D). In cirrhotic patients, the 1-, 2-, 3-, 4-, and 5-year cumulative HCC incidence rates starting 5 years after NUC treatment initiation were 5.5%, 10.2%, 13.8%, 17.6%, and 20.1%, respectively (Figure 2C). Starting 10 years after NUC treatment initiation, the rates were 1.8%, 5.6%, 7.6%, 11.8%, and 11.8%, respectively (Figure 2D). These rates were lower than those reported during the first 5 years after NUC treatment initiation: 7.1% at 1 year, 16.8% at 2 years, 26.0% at 3 years, 30.0% at 4 years, and 36.8% at 5 years (Figure 1B). The complementary

log-log plots for cirrhotic patients initially increased but appeared to level off over time (Supporting Information S2: Figure S2). When the baseline characteristics of cirrhotic patients at the start of NUC treatment were compared, those who developed HCC within 5 years had a higher proportion of patients with a low BMI and lower platelet counts and albumin levels than did those who developed HCC more than 5 years after NUC treatment initiation (Table 5).

3.6 | The HCC Incidence Rate in Noncirrhotic Patients Remained at the Same Level After Long-Term NUC Treatment

In noncirrhotic patients, the 1-, 2-, 3-, 4-, and 5-year cumulative HCC incidence rates starting 5 years after NUC treatment initiation were 1.2%, 3.2%, 4.3%, 4.8%, and 5.8%, respectively (Figure 2C). Similarly, starting 10 years after NUC treatment initiation, the rates were 1.1%, 2.0%, 3.0%, 3.8%, and 4.8%, respectively (Figure 2D). These rates were comparable to those reported during the first 5 years after NUC treatment initiation:






FIGURE 1 | Cumulative incidence of HCC after initiation of NUC treatment. Cumulative incidence of HCC after the initiation of NUC treatment in the total cohort (A). Cumulative incidence of HCC after the initiation of NUC treatment in cirrhotic patients and noncirrhotic patients (B).

1.2% at 1 year, 1.9% at 2 years, 2.8% at 3 years, 3.4% at 4 years, and 4.1% at 5 years (Figure 1B). In noncirrhotic patients, the HCC incidence rate remained at the same level after long-term NUC treatment. The complementary log-log plots for noncirrhotic patients revealed a linear increase (Supporting Information S2: Figure S2). When the baseline characteristics of noncirrhotic patients at the start of NUC treatment were compared, those who developed HCC within 5 years had higher γ -GTP levels than did those who developed HCC more than

5 years after NUC treatment initiation. In noncirrhotic patients, there were no differences in BMI, platelet count, or albumin level between those who developed HCC within 5 years and those who developed HCC more than 5 years after NUC treatment initiation (Table 6). Among noncirrhotic patients, those who developed HCC were older, had lower platelet and albumin levels, and had higher γ -GTP and AFP levels at NUC initiation (Supporting Information S3: Table S11). Among noncirrhotic patients treated with NUC for 5 years, those who developed

TABLE 2 | Risk factors at the start of NUC for incident HCC.

			Ţ	Univariate analysis			Multivariate analysis			
			HR	95% CI	<i>p</i> -value	HR	95% CI	<i>p</i> -value		
Age	years old	per 1-year increase	1.06	1.04-1.07	< 0.0001	1.05	1.03-1.07	< 0.0001		
Sex		Male/female	1.54	1.08-2.18	0.0134	1.69	1.11-2.57	0.0116		
Liver fibrosis		Cirrhosis/ noncirrhosis	6.13	4.43-8.50	< 0.0001	2.63	1.61-4.28	< 0.0001		
BMI	kg/m^2	≥ 23/< 23	1.07	0.73-1.57	0.7197					
Average daily alcohol intake	g	≥ 20/< 20	1.10	0.70-1.71	0.6817					
Diabetes mellitus		Presence/ absence	2.19	1.47–3.25	0.0003	1.01	0.61-1.66	0.9838		
NUC at the start of NUC treatment		LAM, ETV/ TDF, TAF	6.65	0.93–47.7	0.0593					
HBs antigen	IU/mL	$\geq 250/<250$	9.67	1.34-69.7	0.0006					
HBe antigen		Positive/negative	0.85	0.61-1.19	0.3455					
HBV DNA	Log IU/mL	≥ 3.0/< 3.0	1.68	0.62-4.53	0.2672					
HBcrAg	Log U/mL	≥ 3.0/< 3.0	0.48	0.09-2.49	0.3848					
Platelet	$\times~10^4/\\\mu L$	$\begin{array}{c} \text{per 1} \times 10^4 / \mu L \\ \text{increase} \end{array}$	0.86	0.83-0.89	< 0.0001	0.94	0.89-0.99	0.0135		
AST	U/L	per 1 U/L increase	0.999	0.998-1.001	0.4719					
ALT	U/L	per 1 U/L increase	0.99902	0.99782-0.99999	0.0467	0.99852	0.99679-0.99992	0.0361		
γ-GTP	U/L	per 1 U/L increase	1.002	1.001-1.003	0.0008	1.003	1.002-1.005	0.0005		
Total bilirubin	mg/dL	per 1 mg/dL increase	1.11	1.04–1.16	0.0047	1.09	0.94-1.26	0.2433		
Albumin	g/dL	per 1 g/dL increase	0.43	0.33-0.55	< 0.0001	0.84	0.57-1.27	0.4115		
PT	%	per 1% increase	0.97	0.96-0.98	< 0.0001	1.00	0.99-1.02	0.8059		
AFP	ng/mL	per 1 ng/mL increase	1.001	1.000-1.002	0.0470	1.00	0.99-1.02	0.3875		
Creatinine	mg/dL	per 1 mg/dL increase	1.11	0.61-1.51	0.6549					

HCC thereafter were older; had a higher diabetes incidence at NUC initiation; had lower platelet counts; and had higher AST, γ -GTP, and AFP levels at 5 years post-NUC initiation (Supporting Information S3: Table S12).

4 | Discussion

We clearly demonstrated that the risk of HCC occurrence persists for a long time after NUC treatment initiation in the present study. Additionally, we revealed that older age, the presence of cirrhosis, and a high γ -GTP level are risk factors for subsequent HCC occurrence 5 years after the start of NUC

treatment, whereas the presence of cirrhosis and diabetes at baseline are risk factors for subsequent incident HCC 10 years after the start of NUC treatment. The mean observation period after the initiation of NUC treatment in the present study exceeded 12 years, making this study valuable.

Our study revealed that in noncirrhotic patients, the risk persists at a comparable level even more than 10 years after starting NUC treatment. The factors related to HBV-induced incident HCC include the accumulation of genetic abnormalities due to chronic inflammation and regeneration, genome instability due to the integration of the HBV genome into the host genome [14, 15], DNA methylation [16], and direct carcinogenic effects of the HBx protein [17] or HBV preS/S proteins [18]. NUC

TABLE 3 | Risk factors for incident HCC 5 years after the initiation of NUC treatment.

			Univariate analysis		Multivariate a		nalysis	
			HR	95% CI	<i>p</i> -value	HR	95% CI	<i>p</i> -value
Age	years old	per 1-year increase	1.05	1.03-1.08	< 0.0001	1.06	1.03-1.09	< 0.0001
Sex		Male/female	1.28	0.78 - 2.10	0.3261			
Liver fibrosis		Cirrhosis/noncirrhosis	3.35	2.05-5.49	< 0.0001	2.54	1.31-4.96	0.0077
BMI	kg/m ²	≥ 23/< 23	0.68	0.39-1.19	0.1779			
Average daily alcohol intake	g	≥ 20/< 20	1.26	0.69-2.29	0.4519			
Diabetes mellitus		Presence/absence	2.60	1.49-4.56	0.0023	1.58	0.80-3.13	0.2088
HBs antigen*	IU/mL	≥ 250/< 250	1.03	0.42-2.51	0.9529			
HBe antigen*		Positive/negative	0.75	0.37-1.52	0.4126			
HBV DNA*	Log IU/mL	$\geq 3.0 / < 3.0$	0.23	0.03-1.68	0.0616			
HBcrAg*	Log U/mL	$\geq 3.0 / < 3.0$	0.75	0.14-4.09	0.7410			
Platelet*	$\times~10^4/\mu L$	per 1 \times $10^4/\mu L$ increase	0.91	0.86-0.95	< 0.0001	0.96	0.91-1.03	0.2399
AST*	U/L	per 1 U/L increase	1.006	0.996-1.012	0.2097			
ALT*	U/L	per 1 U/L increase	1.000	0.991-1.004	0.9495			
γ-GTP*	U/L	per 1 U/L increase	1.008	1.005-1.010	< 0.0001	1.011	1.007-1.014	< 0.0001
Total bilirubin*	mg/dL	per 1 mg/dL increase	1.03	0.55-1.72	0.9074			
Albumin*	g/dL	per 1 g/dL increase	1.08	0.52-2.33	0.8392			
PT*	%	per 1% increase	0.99	0.97-1.02	0.5134			
AFP*	ng/mL	per 1 ng/mL increase	1.014	1.007-1.022	< 0.0001	1.02	1.01-1.03	0.0006
Creatinine*	mg/dL	per 1 mg/dL increase	1.39	0.85-1.81	0.1529			


^{*} At 5 years after the initiation of NUC treatment.

 TABLE 4
 Risk factors for incident HCC 10 years after NUC treatment initiation.

			Univariate analysis		Multivariate ar		alysis	
			HR	95% CI	<i>p</i> -value	HR	95% CI	<i>p</i> -value
Age	years old	per 1-year increase	1.04	1.00-1.08	0.0327	1.035	0.995-1.076	0.0796
Sex		Male/female	1.80	0.75-4.30	0.1729			
Liver fibrosis		Cirrhosis/noncirrhosis	2.78	1.20-6.45	0.0273	2.63	1.13-6.10	0.0357
BMI	kg/m ²	≥ 23/< 23	1.15	0.47-2.83	0.7630			
Average daily alcohol intake	g	≥ 20/< 20	0.94	0.28-3.12	0.9128			
Diabetes mellitus		Presence/absence	3.52	1.47-8.43	0.0114	3.06	1.27-7.38	0.0234
HBs antigen*	IU/mL	$\geq 250/<250$	0.63	0.23 - 1.75	0.3820			
HBe antigen*		Positive/negative	0.94	0.12 - 7.53	0.9535			
HBV DNA*	Log IU/mL	$\geq 3.0 / < 3.0$	0.00	0-	0.9993			
HBcrAg*	Log U/mL	$\geq 3.0 / < 3.0$	0.67	0.12 - 3.75	0.6526			
Platelet*	$\times~10^4/\mu L$	per 1 \times $10^4/\mu L$ increase	0.95	0.86-1.04	0.2885			
AST*	U/L	per 1 U/L increase	1.01	0.97 - 1.04	0.4803			
ALT*	U/L	per 1 U/L increase	0.99	0.94-1.01	0.6100			
γ-GTP*	U/L	per 1 U/L increase	1.006	0.996-1.013	0.1893			
Total bilirubin*	mg/dL	per 1 mg/dL increase	1.89	0.66-4.13	0.2081			
Albumin*	g/dL	per 1 g/dL increase	1.25	0.38-6.53	0.7497			
PT*	%	per 1% increase	0.98	0.95-1.02	0.4085			
AFP*	ng/mL	per 1 ng/mL increase	0.99	0.82 - 1.02	0.6644			
Creatinine*	mg/dL	per 1 mg/dL increase	0.53	0.02-1.40	0.4786			

 $[\]ensuremath{^*}$ At 10 years after the initiation of NUC treatment.

(A) (B)






FIGURE 2 | Cumulative incidence of HCC after 5 years and 10 years of NUC treatment. Cumulative incidence of HCC after 5 years of NUC treatment in the total cohort (A). Cumulative incidence of HCC after 10 years of NUC treatment in the total cohort (B). Cumulative HCC incidence after 5 years of NUC treatment in cirrhotic patients and noncirrhotic patients (C). Cumulative HCC incidence after 10 years of NUC treatment in cirrhotic patients and noncirrhotic patients (D).

treatment suppresses chronic hepatitis and inhibits incident HCC by suppressing serum HBV DNA but does not eliminate HBV genome integration, DNA methylation, the HBx protein, or the HBV preS/S proteins. The persistence of the risk of incident HCC more than 15 years after the initiation of NUC treatment in noncirrhotic patients may reflect that the risk of incident HCC due to HBV genome integration, DNA methylation, the HBx protein, and the HBV preS/S proteins persists

over time. In cirrhotic patients, the cumulative HCC incidence after 5 and 10 years of NUC treatment was lower than that immediately after NUC treatment initiation. The observation of a suppressive effect on incident HCC after long-term NUC administration in cirrhotic patients suggests that chronic inflammation plays a significant role in the development of incident HCC in this population. However, the data in Table 5 suggest that patients who developed HCC within 5 years were

TABLE 5 | Characteristics of the cirrhotic patients at the start of NUC treatment and those who developed HCC within 5 years or more than 5 years after NUC treatment initiation.

	Within 5 years	More than 5 years	<i>p</i> -value
Number of patients	56	25	
Age (median, range)	60 (37-80)	59 (43-69)	0.4610
Sex (male, female)	40/16 (71.4%, 28.6%)	16/9 (64.0%, 36.0%)	0.5038
BMI (kg/m^2) (< 23, 23 \leq)	14/25 (35.9%, 64.1%)	12/6 (66.7%, 33.3%)	0.0302
Average daily alcohol intake (g) (< 20, 20 \leq)	20/5 (80.0%, 20.0%)	8/7 (53.3%, 46.7%)	0.0748
Diabetes mellitus (+, -)	13/43 (23.2%, 76.8%)	8/17 (32.0%, 68.0%)	0.4046
HBs antigen (IU/mL) ($< 250, 250 \le$)	0/21 (0%, 100%)	0/12 (0%, 100%)	_
HBe antigen $(+, -)$	25/30 (45.5%, 54.5%)	15/9 (62.5%, 37.5%)	0.1634
HBV DNA (log IU/mL) ($< 3.0, 3.0 \le$)	2/54 (3.6%, 96.4%)	0/25 (0%, 100%)	0.3387
HBcrAg (log U/mL) ($< 3.0, 3.0 \le$)	1/2 (33.3%, 66.7%)	0/1 (0%, 100%)	0.5050
Platelet ($\times~10^4/\mu L$) (median, range)	8.2 (3.4–16.9)	11.4 (5.4–20.5)	0.0041
AST (IU/L) (median, range)	60 (25–211)	55 (29-436)	0.3571
ALT (IU/L) (median, range)	58 (20-555)	51 (7-689)	0.7242
γ-GTP (IU/L) (median, range)	60 (19-491)	65 (19–336)	0.6907
Total bilirubin (mg/dL) (median, range)	1.1 (0.5–28.5)	0.9 (0.4–3.9)	0.1679
Albumin (g/dL) (median, range)	3.4 (1.6-4.6)	3.8 (2.3-4.7)	0.0270
PT (%) (median, range)	65 (42–98)	77 (49–96)	0.0699
AFP (ng/mL) (median, range)	15 (2–2370)	13 (3–205)	0.6187
Creatinine (mg/dL) (median, range)	0.73 (0.50-1.30)	0.71 (0.057–3.10)	0.4064

TABLE 6 | Characteristics of the noncirrhotic patients at the start of NUC treatment and those who developed HCC within 5 years or more than 5 years after NUC treatment initiation.

	Within 5 years	More than 5 years	<i>p</i> -value
Number of patients	23	43	
Age (median, range)	59 (41-64)	56 (36–73)	0.4187
Sex (male, female)	17/6 (73.9%, 26.1%)	28/15 (65.1%, 34.9%)	0.4647
BMI (kg/m^2) (< 23, 23 \leq)	7/8 (46.7%, 53.3%)	20/15 (57.1%, 42.9%)	0.4958
Average daily alcohol intake (g) ($< 20, 20 \le$)	3/9 (25.0%, 75.0%)	17/12 (58.6%, 41.4%)	0.2585
Diabetes mellitus (+, -)	2/21 (8.7%, 91.3%)	8/35 (18.6%, 81.4%)	0.2847
HBs antigen (IU/mL) (< 250, 250 ≤)	0/6 (0%, 100%)	1/23 (4.2%, 95.8%)	0.6111
HBe antigen $(+, -)$	6/17 (26.1%, 73.9%)	17/25 (40.5%, 59.5%)	0.2640
HBV DNA (log IU/mL) ($<$ 3.0, 3.0 $≤$)	1/22 (4.4%, 95.6%)	1/42 (2.3%, 97.7%)	0.6479
HBcrAg (log U/mL) ($< 3.0, 3.0 \le$)	0/0	1/2 (33.3%, 66.7%)	_
Platelet ($\times 10^4/\mu L$) (median, range)	14.2 (8.2–22.6)	14.4 (6.3–25.8)	0.8823
AST (IU/L) (median, range)	58 (37-468)	58 (26-1533)	0.7313
ALT (IU/L) (median, range)	55 (27-617)	63 (26–1288)	0.8664
γ-GTP (IU/L) (median, range)	77 (36–987)	65 (16-315)	0.0168
Total bilirubin (mg/dL) (median, range)	0.9 (0.4–1.8)	0.8 (0.4–5.8)	0.4558
Albumin (g/dL) (median, range)	4.0 (3.3-4.4)	3.9 (3.2-4.8)	0.8184
PT (%) (median, range)	84 (51–107)	84 (39–115)	0.5047
AFP (ng/mL) (median, range)	11 (2–1509)	10 (2–175)	0.5692
Creatinine (mg/dL) (median, range)	0.74 (0.40-0.95)	0.74 (0.50-1.03)	0.7315

more likely to have advanced cirrhosis than patients who developed HCC more than 5 years after treatment initiation. The reduction in HCC incidence after long-term NUC treatment in cirrhotic patients may simply be due to a decline in the number of high-risk patients over time.

Previous studies reported that advanced-stage liver fibrosis at the start of NUC treatment is an important predictor of incident HCC despite antiviral therapy [19–21]. Additionally, it has been reported that an elevated FIB-4 index, which estimates fibrosis, after starting NUC treatment is a risk factor for the development of incident HCC during NUC therapy [22, 23]. Although previous research has showed that NUC treatment can improve fibrosis, even in patients with cirrhosis [24, 25], our study revealed that individuals with cirrhosis at the initiation of NUC therapy remain at a significantly greater risk of developing HCC than those without cirrhosis, even more than 10 years after starting NUC treatment. From the perspective of suppressing incident HCC, initiating NUC treatment in HBV patients before they progress to cirrhosis may be critical.

Huang CF et al. reported that a γ -GTP level > 25 U/L at 6 months after NUC treatment initiation is a risk factor associated with the development of HCC in the following 6 months [26]. Sometani E et al. reported that a high γ -GTP level was a risk factor for HCC in CHB patients treated with NUCs for more than 1 year who had suppressed HBV DNA titers [27]. γ -GTP is a well-known biological marker of excessive ethanol consumption and is associated with metabolic dysfunction-associated steatotic liver disease (MASLD) [28]. In patients with chronic hepatitis C without alcohol consumption or diabetes mellitus, γ-GTP at the time of sustained virological response (SVR) has been reported to be correlated with growth differentiation factor 15 (GDF15), a marker of mitochondrial dysfunction. Additionally, single nucleotide polymorphisms (SNPs) in ZNF827 and GDF15 have been associated with high GGT levels [29]. In the present study, GDF15 and SNPs were not examined, which is a limitation of the present study. Patients with higher alcohol intake had higher y-GTP levels than did those with lower alcohol intake, and patients with diabetes mellitus had higher γ -GTP levels than did those without diabetes mellitus. The finding that a high γ -GTP level is a risk factor for HCC suggests that the presence of comorbid alcohol-associated liver disease (ALD) or MASLD is a risk factor for HCC.

Diabetes was identified as contributing to the development of HCC more than 10 years after NUC treatment initiation. Because the comorbidity rate of diabetes is high in MASLD patients [30], the coexistence of MASLD may have contributed to the development of HCC more than 10 years after NUC treatment initiation. It has been reported that in CHB patients with diabetes, the hyperglycemic burden is associated with the development of HCC, regardless of the use of anti-HBV therapy or baseline HBV DNA levels [31]. Furthermore, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of incident HCC in CHB patients with diabetes [32]. Future studies are needed to determine whether glycemic control reduces the risk of incident HCC in patients with diabetes receiving NUC treatment.

Interestingly, in the present study, the HBs antigen, HBe antigen, hepatitis B virus core-related antigen (HBcrAg), and HBV

DNA were not risk factors for incident HCC under NUC treatment initiation. Recently, new HBV markers, including HBV RNA [33], iTACT-HBcrAg [12], and the hepatitis B surface antigen glycan isomer (HBsAgGi)/HBs antigen ratio [34], have been reported to be valuable predictors of HCC incidence during NUC therapy. These novel HBV markers were not examined in the present study. In the future, the predictive ability of these novel HBV markers for incident HCC during NUC treatment is expected to be examined in cohorts with longer observation periods, such as in the present study.

In conclusion, the HCC incidence rate persists for at least 15 years after NUC treatment initiation. Cirrhosis at the start of NUC therapy was strongly associated with a higher risk of HCC, even after 10 years. However, in noncirrhotic patients, the risk remains at a similar level even after a decade of NUC treatment.

Acknowledgments

This study was funded by the Japan Agency for Medical Research and Development (AMED) under grant numbers JP24fk0310512 and JP25fk0310534.

Conflicts of Interest

Hayato Hikita and Tomohide Tatsumi are Editorial Board members of Hepatology Research and coauthors of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. Tetsuo Takehara is a former member of the Hepatology Research Editorial Board and a coauthor of this article. Tetsuo Takehara received research grants from Gilead Sciences Inc., GSK plc, and Bristol Myers Squibb. Tetsuo Takehara and Hayato Hikita received lecture fees from Gilead Sciences.

References

- 1. H. Sung, J. Ferlay, R. L. Siegel, et al., "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," *CA: A Cancer Journal for Clinicians* 71, no. 3 (May 2021): 209–249, https://doi.org/10.3322/caac.21660.
- 2. W. J. Jeng, G. V. Papatheodoridis, and A. S. F. Lok, "Hepatitis B," *Lancet*. 401, no. 10381 (March 2023): 1039–1052, https://doi.org/10. 1016/s0140-6736(22)01468-4.
- 3. N. A. Terrault, N. H. Bzowej, K. M. Chang, J. P. Hwang, M. M. Jonas, and M. H. Murad, "AASLD Guidelines for Treatment of Chronic Hepatitis B," *Hepatology* 63, no. 1 (January 2016): 261–283, https://doi.org/10.1002/hep.28156.
- 4. K. Murai, T. Kodama, H. Hikita, et al., "Inhibition of Nonhomologous End Joining-Mediated DNA Repair Enhances Anti-HBV CRISPR Therapy," *Hepatology Communications* 6, no. 9 (September 2022): 2474–2487, https://doi.org/10.1002/hep4.2014.
- 5. Y. F. Liaw, J. J. Sung, W. C. Chow, et al., "Lamivudine for Patients With Chronic Hepatitis B and Advanced Liver Disease," *New England Journal of Medicine* 351, no. 15 (October 2004): 1521–1531, https://doi.org/10.1056/nejmoa033364.
- 6. T. Hosaka, F. Suzuki, M. Kobayashi, et al., "Long-Term Entecavir Treatment Reduces Hepatocellular Carcinoma Incidence in Patients With Hepatitis B Virus Infection," *Hepatology* 58, no. 1 (July 2013): 98–107, https://doi.org/10.1002/hep.26180.
- 7. M. H. Nguyen, H. I. Yang, A. Le, et al., "Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-

- Matched Study," *Journal of Infectious Diseases* 219 (January 2019): 10–18, https://doi.org/10.1093/infdis/jiy391.
- 8. G. V. Papatheodoridis, P. Lampertico, S. Manolakopoulos, and A. Lok, "Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Therapy: A Systematic Review," *Journal of Hepatology* 53, no. 2 (August 2010): 348–356, https://doi.org/10.1016/j.jhep.2010.02.035.
- 9. H. Enomoto, N. Akuta, H. Hikita, et al., "Etiological Changes of Liver Cirrhosis and Hepatocellular Carcinoma-Complicated Liver Cirrhosis in Japan: Updated Nationwide Survey From 2018 to 2021," *Hepatology Research* 54, no. 8 (April 2024): 763–772, https://doi.org/10.1111/hepr.14047.
- 10. L. Lin, L. Yan, Y. Liu, C. Qu, J. Ni, and H. Li, "The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies From 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results From the Global Burden of Disease Study 2017," *Liver Cancer* 9, no. 5 (September 2020): 563–582, https://doi.org/10.1159/000508568.
- 11. Z. Liu, Y. Jiang, H. Yuan, et al., "The Trends in Incidence of Primary Liver Cancer Caused by Specific Etiologies: Results From the Global Burden of Disease Study 2016 and Implications for Liver Cancer Prevention," *Journal of Hepatology* 70, no. 4 (April 2019): 674–683, https://doi.org/10.1016/j.jhep.2018.12.001.
- 12. T. Hosaka, F. Suzuki, M. Kobayashi, et al., "Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir," *Hepatology Communications* 6, no. 1 (January 2022): 36–49, https://doi.org/10.1002/hep4.1819.
- 13. Y. Kanda, "Investigation of the Freely Available Easy-To-Use Software 'EZR' for Medical Statistics," *Bone Marrow Transplantation* 48, no. 3 (March 2013): 452–458, https://doi.org/10.1038/bmt.2012.244.
- 14. M. Levrero and J. Zucman-Rossi, "Mechanisms of HBV-Induced Hepatocellular Carcinoma," *Journal of Hepatology* 64, no. 1 (April 2016): S84–S101, https://doi.org/10.1016/j.jhep.2016.02.021.
- 15. H. Takeda, A. Takai, T. Inuzuka, and H. Marusawa, "Genetic Basis of Hepatitis Virus-Associated Hepatocellular Carcinoma: Linkage Between Infection, Inflammation, and Tumorigenesis," *Journal of Gastroenterology* 52, no. 1 (January 2017): 26–38, https://doi.org/10.1007/s00535-016-1273-2.
- 16. J. Zhao, G. Wu, F. Bu, et al., "Epigenetic Silence of Ankyrin-Repeat-Containing, SH3-Domain-Containing, and Proline-Rich-Region- Containing Protein 1 (ASPP1) and ASPP2 Genes Promotes Tumor Growth in Hepatitis B Virus-Positive Hepatocellular Carcinoma," *Hepatology* 51 (January 2010): 142–153, https://doi.org/10.1002/hep.23247.
- 17. K. Sekiba, M. Otsuka, K. Funato, et al., "HBx-Induced Degradation of Smc5/6 Complex Impairs Homologous Recombination-Mediated Repair of Damaged DNA," *Journal of Hepatology* 76, no. 1 (January 2022): 53–62, https://doi.org/10.1016/j.jhep.2021.08.010.
- 18. L. H. Wang, W. Huang, M. D. Lai, and I. J. Su, "Aberrant Cyclin A Expression and Centrosome Overduplication Induced by Hepatitis B Virus Pre-S2 Mutants and Its Implication in Hepatocarcinogenesis," *Carcinogenesis* 33, no. 2 (February 2012): 466–472, https://doi.org/10.1093/carcin/bgr296.
- 19. S. Kaneko, M. Kurosaki, T. Mashiba, et al., "Risk Factors for Hepatocellular Carcinoma at Baseline and 1 Year After Initiation of Nucleos (t)ide Analog Therapy for Chronic Hepatitis B," *Journal of Medical Virology* 95 (January 2023): e28210, https://doi.org/10.1002/jmv.28210.
- 20. Y. Sun, Y. Zhang, Y. Xu, et al., "Real-World Study on Clinical Outcomes of Nucleos(t)ide Analogues Antiviral Therapy in Patients With Chronic Hepatitis B," *Epidemiology and Infection* 147 (January 2019): e193, https://doi.org/10.1017/s0950268819000815.
- 21. R. Yamada, N. Hiramatsu, T. Oze, et al., "Impact of Alpha-Fetoprotein on Hepatocellular Carcinoma Development During Entecavir Treatment of Chronic Hepatitis B Virus Infection," *Journal of Gastroenterology* 50, no. 7 (July 2015): 785–794, https://doi.org/10.1007/s00535-014-1010-7.

- 22. J. Inoue, T. Akahane, T. Kobayashi, et al., "Usefulness of the Fibrosis-4 Index and Alanine Aminotransferase at 1 Year of Nucleos(t)ide Analog Treatment for Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients," *Hepatology Research* 54, no. 2 (February 2024): 131–141, https://doi.org/10.1111/hepr.13957.
- 23. A. Kuwano, M. Miyazaki, M. Yada, et al., "FIB-4 Index and Serum α-Fetoprotein Are Useful Predictors of Hepatocellular Carcinoma Occurrence in Hepatitis B Patients With Nucleos(t)ide Analogs Therapy," *Experimental and Therapeutic Medicine* 26, no. 3 (September 2023): 441, https://doi.org/10.3892/etm.2023.12140.
- 24. T. T. Chang, Y. F. Liaw, S. S. Wu, et al., "Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients With Chronic Hepatitis B," *Hepatology* 52, no. 3 (September 2010): 886–893, https://doi.org/10.1002/hep.23785.
- 25. P. Marcellin, E. Gane, M. Buti, et al., "Regression of Cirrhosis During Treatment With Tenofovir Disoproxil Fumarate for Chronic Hepatitis B: A 5-Year Open-Label Follow-Up Study," *Lancet* 381, no. 9865 (February 2013): 468–475, https://doi.org/10.1016/s0140-6736(12)61425-1.
- 26. C. F. Huang, T. Y. Jang, D. W. Jun, et al., "On-Treatment Gamma-Glutamyl Transferase Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis B Patients," *Liver International* 42, no. 1 (January 2022): 59–68, https://doi.org/10.1111/liv.15085.
- 27. E. Sometani, H. Hikita, K. Murai, et al., "High Serum Growth Differentiation Factor 15 Is a Risk Factor for the Occurrence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogs," *Hepatology Research* 55, no. 1 (September 2024): 22–33, https://doi.org/10.1111/hepr.14111.
- 28. S. K. Kunutsor, "Gamma-Glutamyltransferase-Friend or Foe within?," *Liver International* 36, no. 12 (December 2016): 1723–1734, https://doi.org/10.1111/liv.13221.
- 29. M. Murakawa, M. Nakagawa, H. Nishimura, et al., "High Serum Gamma-Glutamyltransferase Level After Hepatitis C Virus Elimination Is a Risk Factor for the Development of Hepatocellular Carcinoma," *Hepatology Research* 54, no. 12 (December 2024): 1128–1138, https://doi.org/10.1111/hepr.14094.
- 30. A. Mantovani, G. Petracca, G. Beatrice, H. Tilg, C. D. Byrne, and G. Targher, "Non-Alcoholic Fatty Liver Disease and Risk of Incident Diabetes Mellitus: An Updated Meta-Analysis of 501 022 Adult Individuals," *Gut* 70, no. 5 (May 2021): 962–969, https://doi.org/10.1136/gutjnl-2020-322572.
- 31. L. Y. Mak, R. W. Hui, C. H. Lee, et al., "Glycemic Burden and the Risk of Adverse Hepatic Outcomes in Patients With Chronic Hepatitis B With Type 2 Diabetes," *Hepatology* 77 (February 2023): 606–618, https://doi.org/10.1002/hep.32716.
- 32. C. H. Lee, L. Y. Mak, E. H. Tang, et al., "SGLT2i Reduces Risk of Developing HCC in Patients With Co-Existing Type 2 Diabetes and Hepatitis B Infection: A Territory-Wide Cohort Study in Hong Kong," *Hepatology* 78 (November 2023): 1569–1580, https://doi.org/10.1097/hep.00000000000000404.
- 33. L. Y. Mak, Q. Huang, D. K. Wong, et al., "Residual HBV DNA and pgRNA Viraemia Is Associated With Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Antiviral Therapy," *Journal of Gastroenterology* 56, no. 5 (May 2021): 479–488, https://doi.org/10.1007/s00535-021-01780-5.
- 34. R. Kozuka, M. Enomoto, Y. Yukawa-Muto, et al., "Hepatitis B Surface Antigen Glycan Isomer Is a Predictor of the Development of Hepatocellular Carcinoma During Nucleoside/Nucleotide Analog Therapy," *Hepatology Research* 54, no. 7 (February 2024): 615–626, https://doi.org/10.1111/hepr.14016.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.